Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: A preliminary study

Thrombosis Research

Volumn 112, Issue 1-2, 2003, Pages 59-64

  Jurasz, Paul ^a,b   North, Scott ^a   Venner, Peter ^a   Radomski, Marek W ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Aggregometry; Cancer; Matrix metalloproteinases; Platelets

Indexed keywords

COLLAGEN; GELATIN; GELATINASE A;

ADULT; AGED; ARTICLE; CANCER PATIENT; CELL ISOLATION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; ZYMOGRAPHY;

EID: 0842346103     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.10.012     Document Type: Article

References (42)

1. Quinn M., Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality: Part I. International comparisons. BJU Int. 90:2002;162-173.
2. Kleiner D.E., Stetler-Stevenson W.G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol. 43:1999;S42-S51.
3. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:1980;67-68.
4. MacDougall J.R., Matrisian L.M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 14:1995;351-362.
5. Stearns M.E., Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 53:1993;878-883.
6. Hamdy F.C., Fadlon E.J., Cottam D., Lawry J., Thurrel W., Silcocks P.B. et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer. 69:1994;177-182.
7. Stearns M.E., Stearns M. Immunohistochemical studies of activated metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol. Res. 8:1996;63-67.
8. Stearns M., Stearns M.E. Evidence for increased activated metalloproteinase-2 (MMP-2a) expression associated with human prostate cancer progression. Oncol. Res. 8:1996;69-75.
9. Nemeth J.A., Yousif R., Herzog M., Che M., Upadhyay J., Shekarriz B.et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J. Natl. Cancer Inst. 94:2002;17-25.
10. Gohji K., Fujimoto N., Hara I., Fujii A., Gotoh A., Okada H.et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer. 79:1998;96-101.
11. Jung K., Krell H.W., Ortel B., Hasan T., Romer A., Schnorr D.et al. Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. Prostate. 54:2003;206-211.
12. Sawicki G., Salas E., Murat J., Miszta-Lane H., Radomski M.W. Release of gelatinase A during platelet activation mediates aggregation. Nature. 386:1997;616-619.
13. Radomski A., Stewart M.W., Jurasz P., Radomski M.W. Pharmacological characteristics of solid-phase von Willebrand factor in human platelets. Br. J. Pharmacol. 5:2001;1013-1020.
14. Honn K.V., Tang D.G., Chen Y.Q. Platelets and cancer metastasis: more than epiphenomenon. Semin. Thromb. Hemost. 18:1992;392-415.
15. Malik A.B. Pulmonary microembolism. Physiol. Rev. 63:1983;1114-1207.
16. Poggi A., Stella M., Donati M.B. The importance of blood cell-vessel wall interactions in tumour metastasis. Baillieres Clin. Haematol. 6:1993;731-752.
17. Philippe C., Philippe B., Fouqueray B., Perez J., Lebret M., Baud L. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am. J. Pathol. 143:1993;1713-1723.
18. Nieswandt B., Hafner M., Echtenacher B., Mannel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59:1999;1295-1300.
19. Salven P., Orpana A., Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res. 5:1999;487-491.
20. Verhuel H.M., Hoekman K., Lupu F., Broxterman H.J., van der Valk P., Kakkar A.K.et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin. Cancer Res. 6:2000;166-171.
21. Trousseau A. Clinique Medicale de l'Hotel-Dieu Paris. 1865;94-96 New Sydenham Society, London.
22. Oefelein F.G., Brant M., Crotty K. Idiopathic thromboembolism as the presenting sign of occult prostate cancer. Urology. 51:1998;775-780.
23. Gasic G.J., Gasic T.B., Stewart C.C. Anti-metastatic effects associated with platelet reduction. Proc. Natl. Acad. Sci. U. S. A. 48:1968;1172-1177.
24. Radomski M.W., Jenkins D.C., Holes L., Moncada S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res. 51:1991;6073-6078.
25. Jurasz P., Sawicki G., Duszyk M., Sawicka J., Miranda C., Mayers I.et al. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res. 61:2001;376-382.
26. Radomski M.W., Moncada S. An improved method for washing platelets with prostacyclin. Thromb. Res. 30:1983;383-389.
27. Radomski A., Jurasz P., Sanders E.J., Overall C.M., Bigg H.F., Edwards D.R.et al. Identification and role of tissue inhibitor of matrix metalloproteinases-4 in human platelets. Br. J. Pharmacol. 13:2002;1330-1338.
28. Sawicki G., Sanders E.J., Salas E., Wozniak M., Rodrigo J., Radomski M.W. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb. Haemost. 80:1998;836-839.
29. Donati M.B. Cancer and thrombosis. Haemostasis. 24:1994;128-131.
30. Remiszewski P., Slodkowska J., Wiatr E., Szopinski J., Radomski P., Plodziszewska M.et al. Pulmonary thromboembolism as the main or secondary cause of death in patients treated for small cell lung cancer. Pneumonol. Alergol. Pol. 67:1999;470-476.
31. Baron J.A., Gridley G., Weiderpass E., Nyren O., Linet M. Venous thromboembolism and cancer. Lancet. 351:1998;1077-1080.
32. Heinmoller E., Weinel R.J., Heidtmann H.H., Salage U., Seitz R., Schmitz I.et al. Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. J. Cancer Res. Clin. Oncol. 122:1996;735-744.
33. Alberio L., Dale G.L. Platelet-collagen interactions: membrane receptors and intracellular signalling pathways. Eur. J. Clin. Invest. 29:1999;1066-1076.
34. Levy-Toledano S. Platelet signal transduction pathways: could we organize them into a 'hierarchy'? Haemostasis. 29:1999;4-15.
35. Martinez M.A., Salas E., Radomski A., Radomski M.W. Matrix metalloproteinase-2 in platelet adhesion to fibrinogen: interactions with nitric oxide. Med. Sci. Monit. 7:2001;646-651.
36. 3. Cell. 85:1996;683-693.
37. 3 in tumor cells expressing membrance-type 1 matrix metalloproteinase. Int. J. Cancer. 86:2000;15-23.
38. Hejna M., Raderer M., Zielinski C.C. Inhibition of metastases by anticoagulants. J. Natl. Cancer Inst. 91:1999;22-36.
39. Nash G.F., Turner L.F., Scully M.F., Kakkar A.K. Platelets and cancer. Lancet. 3:2002;425-430.
40. Trikha M., Nakada M.T. Platelets and cancer: implications for antiangiogenic therapy. Semin. Thromb. Hemost. 28:2002;39-44.
41. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev., Drug Discov. 2:2003;15-28.
42. Ruggeri Z.M. Platelets in atherothrombosis. Nat. Med. 8:2002;1227-1234.